Mirati Therapeutics, Inc.
COMBINATION THERAPIES
Last updated:
Abstract:
The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a mTOR inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
Status:
Application
Type:
Utility
Filling date:
10 Sep 2019
Issue date:
10 Feb 2022